Biocatalysis: A Pharma Perspective

Good pharma? Bad pharma? Better pharma.

Defining Market Access in Brazil: the Pharma Professionals' Perspective.

Poster Presented at the ISPOR 5th Latin America Conference 6 -8 September 2015 Santiago, Chile ©Copyright 2015 Evidências Credibilidade Científica, A Kantar Health Company Alameda Lorena, 131, Conj. 115 e 117, Jardim Paulista São Paulo, SP 01424-001 Brazil + 55-11-3884-0942 www.evidencias.com.br www.kantarhealth.com 1Evidencias – Kantar Health, São Paulo, Brazil; 2Evidencias – Kantar Health, Ca...

Whole organism biocatalysis.

The use of biocatalysts for the industrial synthesis of chemicals has been attracting much attention as an environment-friendly synthetic method. Microbial cells play a leading role in 'chemo-enzymatic synthesis' because of their great diversity. Several microbes with unique catalytic abilities have been found through intensive screening and put to practical use. Besides, advanced molecular bio...

Miniaturization in Biocatalysis

The use of biocatalysts for the production of both consumer goods and building blocks for chemical synthesis is consistently gaining relevance. A significant contribution for recent advances towards further implementation of enzymes and whole cells is related to the developments in miniature reactor technology and insights into flow behavior. Due to the high level of parallelization and reduced...

Big Pharma, little science? A bibliometric perspective on big pharma's R&D decline

There is a widespread perception that pharmaceutical R&D is facing a productivity crisis characterised by stagnation in the numbers of new drug approvals in the face of increasing R&D costs. This study explores pharmaceutical R&D dynamics by examining the publication activities of all R&D laboratories of the major European and US pharmaceutical firms during the period 1995-2009. The empirical f...